Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

R. Kanesvaran; E. Castro; A. Wong; K. Fizazi; M. L.K. Chua; Y. Zhu; H. Malhotra; Y. Miura; J. L. Lee; F. L.T. Chong; Y. S. Pu; C. C. Yen; M. Saad; H. J. Lee; H. Kitamura; K. Prabhash; Q. Zou; G. Curigliano; E. Poon; S. P. Choo; S. Peters; E. Lim; T. Yoshino; G. Pentheroudakis

doi:10.1016/j.esmoop.2022.100518

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

R. Kanesvaran, E. Castro, A. Wong, K. Fizazi, M. L.K. Chua, Y. Zhu, H. Malhotra, Y. Miura, J. L. Lee, F. L.T. Chong, Y. S. Pu, C. C. Yen, M. Saad, H. J. Lee, H. Kitamura, K. Prabhash, Q. Zou, G. Curigliano, E. Poon, S. P. ChooS. Peters, E. Lim, T. Yoshino, G. Pentheroudakis

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of prostate cancer was published in 2020. It was therefore decided, by both the ESMO and the Singapore Society of Oncology (SSO), to convene a special, virtual guidelines meeting in November 2021 to adapt the ESMO 2020 guidelines to take into account the differences associated with the treatment of prostate cancer in Asia. These guidelines represent the consensus opinions reached by experts in the treatment of patients with prostate cancer representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with prostate cancer across the different regions of Asia.

Original language	English
Article number	100518
Journal	ESMO Open
Volume	7
Issue number	4
DOIs	https://doi.org/10.1016/j.esmoop.2022.100518
Publication status	Published - 1 Aug 2022

Keywords

ESMO
Pan-Asian
guidelines
prostate cancer
treatment

Access to Document

10.1016/j.esmoop.2022.100518

Cite this

Kanesvaran, R., Castro, E., Wong, A., Fizazi, K., Chua, M. L. K., Zhu, Y., Malhotra, H., Miura, Y., Lee, J. L., Chong, F. L. T., Pu, Y. S., Yen, C. C., Saad, M., Lee, H. J., Kitamura, H., Prabhash, K., Zou, Q., Curigliano, G., Poon, E., ... Pentheroudakis, G. (2022). Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open, 7(4), Article 100518. https://doi.org/10.1016/j.esmoop.2022.100518

@article{bb2cb91fa0114951a902d7a16c6146ec,

title = "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer",

abstract = "The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of prostate cancer was published in 2020. It was therefore decided, by both the ESMO and the Singapore Society of Oncology (SSO), to convene a special, virtual guidelines meeting in November 2021 to adapt the ESMO 2020 guidelines to take into account the differences associated with the treatment of prostate cancer in Asia. These guidelines represent the consensus opinions reached by experts in the treatment of patients with prostate cancer representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with prostate cancer across the different regions of Asia.",

keywords = "ESMO, Pan-Asian, guidelines, prostate cancer, treatment",

author = "R. Kanesvaran and E. Castro and A. Wong and K. Fizazi and Chua, {M. L.K.} and Y. Zhu and H. Malhotra and Y. Miura and Lee, {J. L.} and Chong, {F. L.T.} and Pu, {Y. S.} and Yen, {C. C.} and M. Saad and Lee, {H. J.} and H. Kitamura and K. Prabhash and Q. Zou and G. Curigliano and E. Poon and Choo, {S. P.} and S. Peters and E. Lim and T. Yoshino and G. Pentheroudakis",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = aug,

day = "1",

doi = "10.1016/j.esmoop.2022.100518",

language = "English",

volume = "7",

journal = "ESMO Open",

issn = "2059-7029",

number = "4",

}

Kanesvaran, R, Castro, E, Wong, A, Fizazi, K, Chua, MLK, Zhu, Y, Malhotra, H, Miura, Y, Lee, JL, Chong, FLT, Pu, YS, Yen, CC, Saad, M, Lee, HJ, Kitamura, H, Prabhash, K, Zou, Q, Curigliano, G, Poon, E, Choo, SP, Peters, S, Lim, E, Yoshino, T & Pentheroudakis, G 2022, 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer', ESMO Open, vol. 7, no. 4, 100518. https://doi.org/10.1016/j.esmoop.2022.100518

TY - JOUR

T1 - Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

AU - Kanesvaran, R.

AU - Castro, E.

AU - Wong, A.

AU - Fizazi, K.

AU - Chua, M. L.K.

AU - Zhu, Y.

AU - Malhotra, H.

AU - Miura, Y.

AU - Lee, J. L.

AU - Chong, F. L.T.

AU - Pu, Y. S.

AU - Yen, C. C.

AU - Saad, M.

AU - Lee, H. J.

AU - Kitamura, H.

AU - Prabhash, K.

AU - Zou, Q.

AU - Curigliano, G.

AU - Poon, E.

AU - Choo, S. P.

AU - Peters, S.

AU - Lim, E.

AU - Yoshino, T.

AU - Pentheroudakis, G.

PY - 2022/8/1

Y1 - 2022/8/1

N2 - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of prostate cancer was published in 2020. It was therefore decided, by both the ESMO and the Singapore Society of Oncology (SSO), to convene a special, virtual guidelines meeting in November 2021 to adapt the ESMO 2020 guidelines to take into account the differences associated with the treatment of prostate cancer in Asia. These guidelines represent the consensus opinions reached by experts in the treatment of patients with prostate cancer representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with prostate cancer across the different regions of Asia.

AB - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of prostate cancer was published in 2020. It was therefore decided, by both the ESMO and the Singapore Society of Oncology (SSO), to convene a special, virtual guidelines meeting in November 2021 to adapt the ESMO 2020 guidelines to take into account the differences associated with the treatment of prostate cancer in Asia. These guidelines represent the consensus opinions reached by experts in the treatment of patients with prostate cancer representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with prostate cancer across the different regions of Asia.

KW - ESMO

KW - Pan-Asian

KW - guidelines

KW - prostate cancer

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85133443930&partnerID=8YFLogxK

U2 - 10.1016/j.esmoop.2022.100518

DO - 10.1016/j.esmoop.2022.100518

M3 - Article

C2 - 35797737

AN - SCOPUS:85133443930

SN - 2059-7029

VL - 7

JO - ESMO Open

JF - ESMO Open

IS - 4

M1 - 100518

ER -

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this